Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ViCToRy: Vorasidenib + PEPIDH1M Vaccine in Recurrent IDH1 Mutant Lower Grade Gliomas
NCT05609994Phase 1Recruiting
- Start
- Jul 2025
- Primary completion
- Aug 2027
- Modality
- Whole Cell Cancer Vaccines, Peptides, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PEPIDH1M and vorasidenib in low-grade glioma (LGG). Primary endpoints: Safety and Adverse Events at 3.5 years and Progression-Free Survival at 10 years. Started Jul 2025; status: recruiting.
02
Drugs
PEPIDH1Mvorasidenib
03
Conditions
low-grade glioma (LGG)
Beyond the preview
Go deeper on NCT05609994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05609994.